top of page

Prof. Liat Drucker

Education

1984-1987 Hebrew University, Rehovot, Israel; B.Sc., Cum Laude

1987-1989 Plant Sciences, Genetics and breeding, Hebrew University, Rehovot, Israel; M.Sc., Cum Laude

1991-1997 Human Molecular Genetics and Biochemistry, Tel-Aviv University, Tel-Aviv, Israel; Ph.D.

Research experience and positions

1986-7      Research assistant, Plant Genetics, Weizmann Institute, Rehovot, Israel

7-10/1986 Visiting scientist, CELL project, Life Sciences, NASA Ames Research Center, California, USA

1987-9      Research and teaching assistant, Genetics and Breeding, Faculty of Agriculture, Hebrew University of Jerusalem, Rehovot, Israel.

1990-1      Researcher, Meir Hospital, Sapir Medical Center, Molecular Genetics, Kfar Sava, Israel

1996-7      Researcher and lab manager, Molecular Genetics, Meir Medical Center, Kfar Sava

1998-        Chief scientist and lab manager, Oncogenetics, Meir Medical Center, Kfar Sava, Israel

2006-11    Lecturer, Department of pathology, Sackler Faculty of Medicine, Tel-Aviv University

2012-21    Senior Lecturer, Department of pathology, Sackler Faculty of Medicine, Tel-Aviv University

2020-        Associate Professor, Department of pathology, Sackler Faculty of Medicine, Tel-Aviv University

Memberships

2001-         Member, Israel Society of Hematology and Blood Transfusion

2005-         Member, Israel Society of Multiple Myeloma

2007-         Member, International Cancer Microenvironment Society (ICMS)

2008-         Member, American Society of Hematology (ASH)

2010-         Member, Israeli Society for Cancer Research (ISCR)

2010-11     Member, European Association for Cancer Research (EACR)

2016-7       Member, Society for Leukocyte Biology (SLB)

2017-         Member, Israel society of Extracellular Vesicles (ISEV)

Honors

2013          Excellence Research Center, Meir Medical Center, Kfar Saba, Israel

2015          Best basic-science lecture, Annual Research Meeting, Meir Medical Center, Kfar-Saba, Israel

2015          Outstanding Scientific Work, Cancer Biology research Center (CBRC), Dead Sea, Israel

2017          Ministry of Science, technology and Space travel award, Israel

2018          Students' academic publication excellence prize, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

2018          Excellence prize for Scientific Research, Dejrassi-Elias Institute of Oncology, Tel Aviv University, Tel Aviv, Israel

2020          Best basic-science lecture, Annual Research Meeting, Meir Medical Center, Kfar-Saba, Israel

Contact Me

Prof. Liat Drucker

Email: druckerl@clalit.org.il
Tel: 972-9-7472466

Kfar Saba, Israel

1200px-Google_Maps_icon.svg.webp

© 2023 by Tel Aviv University. Proudly created with Wix.com

Select Publications

Exp Cell Res: 444(2):114395, 2025

Ribosomal proteins as distinct “passengers” of microvesicles: new semantics in myeloma and mesenchymal stem cells’ communication

Translational Research. 2021 Oct 236:117-132

Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles

Carcinogenesis. 2020 Mar 13;41(1):100-110

BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner

Transl Res. 2019 May;207:83-95.

 doi: 10.1016/j.trsl.2019.01.003.

Niche origin of mesenchymal stem cells derived microvesicles determines opposing effects on NSCLC: Primary versus metastatic

Cell Signal. 2020 Jan;65:109456.

 doi: 10.1016/j.cellsig.2019.109456

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Autophagy. 2016;12(1):1-222.

 doi: 10.1080/15548627.2015.1100356.

Mesenchymal stem cells secretomes' affect multiple myeloma translation initiation

Cell Signal. 2016 Jun;28(6):620-30.

 doi: 10.1016/j.cellsig.2016.03.003

The effect of mesenchymal stem cells' secretome on lung cancer progression is contingent on their origin: primary or metastatic niche

Lab Invest. 2018 Dec;98(12):1549-1561.

 doi: 10.1038/s41374-018-0110-z

Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation

J Leukoc Biol. 2016 Oct;100(4):761-770.

 doi: 10.1189/jlb.3A1115-510RR.

Multiple myeloma and bone marrow mesenchymal stem cells' crosstalk: Effect on translation initiation

Mol Carcinog. 2016 Sep;55(9):1343-54

Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation

Carcinogenesis. 2017 Jul 1;38(7):708-716

Secretome of human bone marrow mesenchymal stem cells: an emerging player in lung cancer progression and mechanisms of translation initiation

Tumour Biol. 2016 Apr;37(4):4755-65

Targeting eIF4GI translation initiation factor affords an attractive therapeutic strategy in multiple myeloma

Cell Signal. 2014 Sep;26(9):1878-87

eIF4E and eIF4GI have distinct and differential imprints on multiple myeloma's proteome and signaling

Oncotarget. 2015 Feb 28;6(6):4315-29

Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E

Int J Oncol. 2015 Feb;46(2):860-70

Reduced elastin in multiple myeloma niche promotes cell proliferation
Myeloma mesenchymal stem cells' bioenergetics afford a novel selective therapeutic target

Oncogenesis 14(1):9, doi: 10.1038/s41389-025-00554-5, 2025

bottom of page